Prostate disease: management options for the primary healthcare team. Report of a working party of the British Prostate Group.
The prostate gland has attracted a remarkable increase in interest in the past few years. The two most common diseases of this gland, benign prostatic hyperplasia and carcinoma of the prostate, have been brought into greater prominence by new diagnostic methods, public interest, and a wider choice of surgical and non-surgical treatments. Uncertainty about the significance of these changes has occurred because of the rapidity of change, the profusion of statements, opinions and promotions, and the relatively little guidance available from the profession. Ten urologists and two general practitioners have reviewed the relevant evidence about these two prostate diseases and the newer diagnostic methods; their conclusions are summarised here. Management options and guidance on clinical practice are also discussed. Because of a number of unresolved diagnostic and management issues, detailed requirements for practice guidelines have not been specified.
Chisholm
G D
GD
University Department of Surgery/Urology, Western General Hospital, Edinburgh, UK.
Carne
S J
SJ
Fitzpatrick
J M
JM
George
N J
NJ
Gingell
J C
JC
Keen
J W
JW
Kirby
R S
RS
Kirk
D
D
O'Donoghue
E P
EP
Peeling
W B
WB
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D008875:Middle Aged; D010173:Palpation; D010348:Patient Care Team; D011320:Primary Health Care; D017430:Prostate-Specific Antigen / Q000032:analysis; D011469:Prostatic Diseases / Q000175:diagnosis / Q000628:therapy*; D011470:Prostatic Hyperplasia / Q000628:therapy; D011471:Prostatic Neoplasms / Q000628:therapy; D012017:Referral and Consultation
D017430:Prostate-Specific Antigen